Xyzagen

Xyzagen is a specialized, service-oriented biotech firm operating as a consultancy and CRO, focusing on pharmacokinetics and clinical pharmacology to de-risk and accelerate client drug development programs. Founded in 2018, it has supported over 100 life science innovators with a comprehensive suite of lab, in vivo, and modeling services. The company generates revenue by providing these scientific and regulatory services, positioning itself as a virtual extension of its clients' R&D teams. Its operational model includes a PHS OLAW-assured vivarium, enabling it to support NIH SBIR grant-funded projects for biotech clients.

Integrated pharmacokinetics consultancy and CRO with wet lab, in vivo vivarium, and quantitative model-informed drug development (MIDD) capabilities including PopPK, PBPK, and pharmacodynamic modeling.

Xyzagen competes in the fragmented CRO and consultancy market, differentiating itself as a boutique PK/PD expert with integrated lab capabilities. It faces competition from large, full-service CROs (e.g., IQVIA, Charles River) and smaller niche consultancies. Its deep therapeutic focus in ophthalmology and neurology is a key differentiator.